Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program

Area of Science:

• Oncology
• Pharmacology
• Patient Care

Background:

• The Cycle Management Program (CMP) was established in 2008 to support patients on oral oncology medications.
• The CMP now covers nine specific oral chemotherapy drugs, addressing the increasing use of these agents in cancer treatment.
• Oral oncology medications offer patient convenience but require increased patient responsibility for administration and monitoring.

Purpose of the Study:

• To assess the utilization patterns of oral oncology medications within the CMP.
• To evaluate the occurrence of adverse events, medication adherence, and discontinuation rates.

Main Methods:

• A retrospective review of 1163 patient-reported assessments from 557 patients in 2013.
• Data included adverse events, adherence markers, and discontinuation reasons from initial, 10-day, 20-day, and first monthly follow-up assessments.

Main Results:

• 1453 adverse events were reported, contributing to 39% of discontinuations and 28% of missed/held doses.
• 101 medication discontinuations were recorded within the first two months of therapy.
• 130 assessments indicated missed or held doses.

Conclusions:

• Pharmacist interventions and patient engagement through programs like the CMP are vital.
• These programs help patients effectively manage complex and high-risk oral oncology medications.